TY - JOUR
T1 - Virological and immunological features of SARS-COV-2 infected children with distinct symptomatology
AU - The CACTUS Study Team
AU - Cotugno, Nicola
AU - Ruggiero, Alessandra
AU - Pascucci, Giuseppe Rubens
AU - Bonfante, Francesco
AU - Petrara, Maria Raffaella
AU - Pighi, Chiara
AU - Cifaldi, Loredana
AU - Zangari, Paola
AU - Bernardi, Stefania
AU - Cursi, Laura
AU - Santilli, Veronica
AU - Manno, Emma Concetta
AU - Amodio, Donato
AU - Linardos, Giulia
AU - Piccioni, Livia
AU - Barbieri, Maria Antonietta
AU - Perrotta, Daniela
AU - Campana, Andrea
AU - Donà, Daniele
AU - Giaquinto, Carlo
AU - Concato, Carlo
AU - Brodin, Petter
AU - Rossi, Paolo
AU - De Rossi, Anita
AU - Palma, Paolo
AU - Romani, Lorenza
AU - Pansa, Paola
AU - Chiurchiu, Sara
AU - Finocchi, Andrea
AU - Cancrini, Caterina
AU - Lancella, Laura
AU - De Luca, Maia
AU - Cutrera, Renato
AU - Villani, Alberto
AU - Morrocchi, Elena
AU - Zicari, Sonia
AU - Putignani, Lorenza
AU - Calò Carducci, Francesca
AU - De Ioris, Maria A.
AU - D'Argenio, Patrizia
AU - degli Atti, Marta Ciofi
AU - D'Amore, Carmen
N1 - Funding Information:
This work was supported by a research grant from Children's Hospital Bambino Ges? and from Ministry of Health Ricerca Corrente 2021 to NC and PP. We would like to thank all patients and guardians who participated in the study and all the CACTUS study nurses team of the COVID-19 Center of ?Bambino Ges? Children's Hospital.? We also thank our laboratory manager Ilaria Pepponi for her key support and Jennifer Faudella and Giulia Neccia for their administrative assistance.
Funding Information:
This work was supported by a research grant from Children's Hospital Bambino Gesù and from Ministry of Health Ricerca Corrente 2021 to NC and PP.
Publisher Copyright:
© 2021 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
PY - 2021/11
Y1 - 2021/11
N2 - Background: Although SARS-CoV-2 immunizations have started in most countries, children are not currently included in the vaccination programs; thus, it remains crucial to define their anti-SARS-CoV-2 immune response in order to minimize the risk for other epidemic waves. This study sought to provide a description of the virology ad anti-SARS-CoV-2 immunity in children with distinct symptomatology. Methods: Between March and July 2020, we recruited 15 SARS-CoV-2 asymptomatic (AS) and 51 symptomatic (SY) children, stratified according to WHO clinical classification. We measured SARS-CoV-2 viral load using ddPCR and qPCR in longitudinally collected nasopharyngeal swab samples. To define anti-SARS-CoV-2 antibodies, we measured neutralization activity and total IgG load (DiaSorin). We also evaluated antigen-specific B and CD8+T cells, using a labeled S1+S2 protein and ICAM expression, respectively. Plasma protein profiling was performed with Olink. Results: Virological profiling showed that AS patients had lower viral load at diagnosis (p =.004) and faster virus clearance (p =.0002) compared with SY patients. Anti-SARS-CoV-2 humoral and cellular response did not appear to be associated with the presence of symptoms. AS and SY patients showed similar titers of SARS-CoV-2 IgG, levels of neutralizing activity, and frequency of Ag-specific B and CD8+ T cells, whereas pro-inflammatory plasma protein profile was found to be associated with symptomatology. Conclusion: We demonstrated the development of anti-SARS-CoV-2 humoral and cellular response with any regard to symptomatology, suggesting the ability of both SY and AS patients to contribute toward herd immunity. The virological profiling of AS patients suggested that they have lower virus load associated with faster virus clearance.
AB - Background: Although SARS-CoV-2 immunizations have started in most countries, children are not currently included in the vaccination programs; thus, it remains crucial to define their anti-SARS-CoV-2 immune response in order to minimize the risk for other epidemic waves. This study sought to provide a description of the virology ad anti-SARS-CoV-2 immunity in children with distinct symptomatology. Methods: Between March and July 2020, we recruited 15 SARS-CoV-2 asymptomatic (AS) and 51 symptomatic (SY) children, stratified according to WHO clinical classification. We measured SARS-CoV-2 viral load using ddPCR and qPCR in longitudinally collected nasopharyngeal swab samples. To define anti-SARS-CoV-2 antibodies, we measured neutralization activity and total IgG load (DiaSorin). We also evaluated antigen-specific B and CD8+T cells, using a labeled S1+S2 protein and ICAM expression, respectively. Plasma protein profiling was performed with Olink. Results: Virological profiling showed that AS patients had lower viral load at diagnosis (p =.004) and faster virus clearance (p =.0002) compared with SY patients. Anti-SARS-CoV-2 humoral and cellular response did not appear to be associated with the presence of symptoms. AS and SY patients showed similar titers of SARS-CoV-2 IgG, levels of neutralizing activity, and frequency of Ag-specific B and CD8+ T cells, whereas pro-inflammatory plasma protein profile was found to be associated with symptomatology. Conclusion: We demonstrated the development of anti-SARS-CoV-2 humoral and cellular response with any regard to symptomatology, suggesting the ability of both SY and AS patients to contribute toward herd immunity. The virological profiling of AS patients suggested that they have lower virus load associated with faster virus clearance.
KW - Ag-specific cellular response
KW - asymptomatic patients
KW - neutralization humoral activity
KW - SARS-CoV-2
KW - symptomatic patients
UR - http://www.scopus.com/inward/record.url?scp=85111852077&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111852077&partnerID=8YFLogxK
U2 - 10.1111/pai.13585
DO - 10.1111/pai.13585
M3 - Article
C2 - 34174102
AN - SCOPUS:85111852077
SN - 0905-6157
VL - 32
SP - 1833
EP - 1842
JO - Pediatric Allergy and Immunology
JF - Pediatric Allergy and Immunology
IS - 8
ER -